Trial Profile
A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Lucitanib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology [CEASED]
- 18 Jul 2022 Results of a Pop PK pooled analysis from five phase 1 and 2 clinical studies: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746 and NCT02109016 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 05 Aug 2019 Status changed to discontinued.
- 04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.